Mizuho Markets Americas LLC Has $6.03 Million Holdings in Abbott Laboratories (NYSE:ABT)

Mizuho Markets Americas LLC trimmed its position in shares of Abbott Laboratories (NYSE:ABT - Free Report) by 7.6% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 52,883 shares of the healthcare product maker's stock after selling 4,324 shares during the period. Mizuho Markets Americas LLC's holdings in Abbott Laboratories were worth $6,029,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently bought and sold shares of the company. First Long Island Investors LLC raised its position in Abbott Laboratories by 19.6% during the third quarter. First Long Island Investors LLC now owns 404,839 shares of the healthcare product maker's stock valued at $46,156,000 after acquiring an additional 66,474 shares in the last quarter. Simplify Asset Management Inc. increased its stake in shares of Abbott Laboratories by 67.3% during the 3rd quarter. Simplify Asset Management Inc. now owns 14,083 shares of the healthcare product maker's stock worth $1,606,000 after purchasing an additional 5,664 shares during the last quarter. Archer Investment Corp raised its holdings in shares of Abbott Laboratories by 3.1% during the 3rd quarter. Archer Investment Corp now owns 3,489 shares of the healthcare product maker's stock valued at $398,000 after purchasing an additional 104 shares in the last quarter. Empowered Funds LLC lifted its stake in shares of Abbott Laboratories by 6.6% in the 3rd quarter. Empowered Funds LLC now owns 52,371 shares of the healthcare product maker's stock valued at $5,971,000 after purchasing an additional 3,265 shares during the last quarter. Finally, Empirical Finance LLC boosted its holdings in Abbott Laboratories by 2.3% in the third quarter. Empirical Finance LLC now owns 60,360 shares of the healthcare product maker's stock worth $6,882,000 after purchasing an additional 1,335 shares in the last quarter. Institutional investors and hedge funds own 75.18% of the company's stock.

Abbott Laboratories Trading Up 0.8 %

Abbott Laboratories stock opened at $115.90 on Friday. Abbott Laboratories has a 12 month low of $97.64 and a 12 month high of $121.64. The stock has a market cap of $201.02 billion, a price-to-earnings ratio of 35.23, a price-to-earnings-growth ratio of 2.73 and a beta of 0.72. The business has a 50 day moving average price of $115.53 and a two-hundred day moving average price of $109.52. The company has a quick ratio of 1.14, a current ratio of 1.60 and a debt-to-equity ratio of 0.32.

Abbott Laboratories (NYSE:ABT - Get Free Report) last issued its earnings results on Wednesday, October 16th. The healthcare product maker reported $1.21 EPS for the quarter, topping the consensus estimate of $1.20 by $0.01. The firm had revenue of $10.64 billion during the quarter, compared to analysts' expectations of $10.55 billion. Abbott Laboratories had a return on equity of 20.18% and a net margin of 13.99%. Abbott Laboratories's quarterly revenue was up 4.9% compared to the same quarter last year. During the same period last year, the business earned $1.14 earnings per share. As a group, equities analysts forecast that Abbott Laboratories will post 4.67 EPS for the current year.

Abbott Laboratories Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Friday, November 15th. Investors of record on Tuesday, October 15th were given a $0.55 dividend. This represents a $2.20 annualized dividend and a yield of 1.90%. The ex-dividend date of this dividend was Tuesday, October 15th. Abbott Laboratories's dividend payout ratio (DPR) is presently 66.87%.

Insiders Place Their Bets

In other Abbott Laboratories news, CEO Robert B. Ford sold 141,679 shares of the company's stock in a transaction on Thursday, September 12th. The stock was sold at an average price of $116.41, for a total value of $16,492,852.39. Following the sale, the chief executive officer now directly owns 220,059 shares in the company, valued at $25,617,068.19. This represents a 39.17 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Corporate insiders own 1.10% of the company's stock.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on ABT shares. Evercore ISI boosted their price target on Abbott Laboratories from $120.00 to $124.00 and gave the stock an "outperform" rating in a research report on Tuesday, October 1st. Piper Sandler boosted their target price on Abbott Laboratories from $131.00 to $133.00 and gave the stock an "overweight" rating in a report on Thursday, October 17th. UBS Group increased their price target on Abbott Laboratories from $143.00 to $146.00 and gave the company a "buy" rating in a report on Thursday, October 17th. Oppenheimer began coverage on shares of Abbott Laboratories in a report on Tuesday, October 8th. They set an "outperform" rating and a $130.00 price objective for the company. Finally, Morgan Stanley lifted their target price on shares of Abbott Laboratories from $107.00 to $117.00 and gave the stock an "equal weight" rating in a report on Thursday, October 17th. Four investment analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $130.07.

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.